ArticleMedical oncology (Northwood, London, England)2025
tRF-22-WE8SPOX52 promotes progression of breast cancer by down-regulating MAP2K4.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
tsRNAs are a novel class of non-coding RNAs. The functions of tsRNAs in breast cancer are still not largely understood. In the present study, we detected expression of tsRNAs in both serum-derived exosomes and breast tumors, and explored the roles of the differentially expressed tsRNAs. We profiled tsRNAs in serum-derived exosomes from breast cancer patients, and explored the functions and mechanisms of tsRNAs via bioinformatics methods, RT-qPCR, transwell assay, cell counting kit-8 assay, colony formation assay, wound healing assay, cell cycle analysis, apoptosis assay, dual-Luciferase reporter assay, and western blot. We identified 34 differentially expressed tsRNAs in serum-derived exosomes. After validation in 15 paired tissues and 80 serums using RT-qPCR and identified tRF-22-WE8SPOX52 as an up-regulated tsRNA. The area under curve for exosomal tRF-22-WE8SPOX52 was 0.859. The overexpression of tRF-22-WE8SPOX52 promoted cell proliferation, migration, and invasion of BC cells while suppressing apoptosis. Similarly, knockdown of tRF-22-WE8SPOX52 also confirmed its effects. Western blot assay and dual luciferase assay showed MAP2K4 is a target of tRF-22-WE8SPOX52. tRF-22-WE8SPOX52 promotes BC by suppressing MAP2K4. tRF-22-WE8SPOX52 is significantly up-regulated in serum-derived exosomes and tumors from breast cancer patients. Exosomal tRF-22-WE8SPOX52 may serve as a potential biomarker for breast cancer.
Indexed as
Identifiers
40493149What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.